Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.

Clinical pharmacology and therapeutics - 1 May 2010

Lerman C, Jepson C, Wileyto E P, Patterson F, Schnoll R, Mroziewicz M, Benowitz N, Tyndale R F

Abstract excerpt

In a placebo-controlled trial, we examined the efficacy of a 6-month ("extended") transdermal nicotine therapy vs. the 8-week ("standard") therapy in 471 Caucasian smokers with either normal or reduced rates of nicotine metabolism as determined at pretreatment. Extended therapy was superior to st...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Cutaneous
Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2A6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Delayed-Action Preparations

Share to Drug Administration Schedule

Share to Longitudinal Studies

Share to Nicotine

Share to Smoking Cessation

Source

Open in PubMed Open full text

Identifiers

PMID: 20336063
DOI: 10.1038/clpt.2010.3
PMCID: PMC3896974

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20336063-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy.PMID 20336063Read ↗

Pharmacogenetic Optimization of Smoking Cessation Treatment.Semantic proximity Read ↗

Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial.Semantic proximity Read ↗

Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.Semantic proximity Read ↗

Smoking Cessation Pharmacogenetics: Analysis of Varenicline and Bupropion in Placebo-Controlled Clinical TrialsSemantic proximity Read ↗

Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.Semantic proximity Read ↗

Nicotine Metabolism Predicted by CYP2A6 Genotypes in Relation to Smoking Cessation: A Systematic Review.Semantic proximity Read ↗

The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.Semantic proximity Read ↗

The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions.Semantic proximity Read ↗

Varenicline for smoking cessation: nausea severity and variation in nicotinic receptor genesSemantic proximity Read ↗

Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.Semantic proximity Read ↗

Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption.Semantic proximity Read ↗

Impact of CYP2A6 Activity on Nicotine Reinforcement and Cue-Reactivity in Daily SmokersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.